Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.3.1.97: glycylpeptide N-tetradecanoyltransferase

This is an abbreviated version!
For detailed information about glycylpeptide N-tetradecanoyltransferase, go to the full flat file.

Word Map on EC 2.3.1.97

Reaction

tetradecanoyl-CoA
+
an N-terminal-glycyl-[protein]
=
CoA
 +
an N-terminal-N-tetradecanoylglycyl-[protein]

Synonyms

CaNMT, cell division control protein 72, dipeptide N-myristoyltransferase 2, glycylpeptide N-tetradecanoyltransferase, glycylpeptide N-tetradecanoyltransferase 1, glycylpeptide N-tetradecanoyltransferase 2, HsNMT1, HsNMT2, LmNMT, More, myristoyl-CoA-protein N-myristoyltransferase, myristoyl-CoA: protein N-myristoyltransferase, myristoyl-CoA:protein N-myristoyltransferase, myristoyl-CoA:protein N-myristoyltransferase 1, myristoyl-CoA:protein N-myristoyltransferase 2, myristoyl-CoA:protein N-myristoyltransferase type 2, myristoyl-coenzyme A:protein N-myristoyl transferase, myristoyl-coenzyme A:protein N-myristoyltransferase, myristoylating enzymes, myristoyltransferase, myristoyltransferase type 1, myristoyltransferase, protein N-, N-myristoyl transferase, N-myristoyltransferase, N-myristoyltransferase 1, N-myristoyltransferase 2, NMT, NMT 1, NMT 2, NMT-1, NMT-2, NMT1, Nmt1p, NMT2, peptide N-myristoyltransferase, peptide N-myristoyltransferase 1, peptide N-myristoyltransferase 2, protein N-myristoyltransferase, PVX_085815, TbNMT, type I N-myristoyltransferase, type II N-myristoyltransferase

ECTree

     2 Transferases
         2.3 Acyltransferases
             2.3.1 Transferring groups other than aminoacyl groups
                2.3.1.97 glycylpeptide N-tetradecanoyltransferase

Inhibitors

Inhibitors on EC 2.3.1.97 - glycylpeptide N-tetradecanoyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000015 mM
(1R,3S)-N-{2-[(cyclopeanthylcarbonyl)amino]-benzothiazol-6-yl}-3-[(2-naphthylmethyl) amino] cyclohexanecarboxamide
competitive with the substrate peptide and non-competitive with myristoyl-CoA. IC50: 0.49 nM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: above 0.00001 mM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000011mM
(2S)-N-(2-cyclohexylethyl)-2-[[N-([3-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl)-L-seryl]amino]heptanamide
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
1,10-phenanthroline
-
0.1 mM, 30% inhibition
1,12-dodecanedicarboxylic acid
IC50 above 100 mM
1,3-dimyristoylglycerol
IC50 above 100 mM
1-(4-(3,5-dichloro-4-((2-methylpyridin-3-yl)methoxy)phenyl)pyridin-2-yl)piperazine
-
3fold selectivity over human isoform NMT1
1-(4-(3,5-dichloro-4-((2-phenylpyridin-3-yl)methoxy)phenyl)-pyridin-2-yl)piperazine
-
3fold selectivity over human isoform NMT1
1-(4-(3,5-dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-piperazine
-
2fold selectivity over human isoform NMT1; 65fold selectivity over human isoform NMT1
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
-
1-acetyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3-dihydro-1H-indole-5-sulfonamide
-
-
1-Bromo-2-fluorotetradecane
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
1-myristoyl-rac-glycerol
IC50 in the range 1-100 mM
1-O-Acetyl-2-fluorotetradecane
-
-
1-Tetradecanal
IC50 in the range 1-100 mM
1-Tetradecanol
IC50 above 100 mM
1-[(diethylamino)methyl]naphthalen-2-ol
-
-
2,6-dichloro-4-(1,2,3,4-tetrahydroisoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
-
-
2,6-dichloro-4-(isoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
IC50 value against amastigotes 0.00015 microM
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-N-(1,5-dimethyl-3-isobutyl-1H-pyrazol-4-yl)benzenesulfonamide
inhibits the enzyme and is fungicidal under partially repressive nmt conditions
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
2,6-dichloro-4-[6-(piperazin-1-yl)pyridin-3-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2-(3,4-dihydroxyphenyl)ethyl 6-deoxy-alpha-L-gulopyranosyl-(1->3)-[alpha-L-ribopyranosyl-(1->6)]-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-L-glucopyranoside
inhibitor identified by screening of chemical libraries using different docking programs, substance is predicted not to inhibit human isoforms
2-(3,4-dihydroxyphenyl)ethyl alpha-L-gulopyranosyl-(1->2)-6-deoxy-alpha-L-gulopyranosyl-(1->3)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-L-glucopyranoside
inhibitor identified by screening of chemical libraries using different docking programs, substance is predicted not to inhibit human isoforms
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
2-(acetylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-(benzylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
2-([2-[(2,3-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2,4-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(3-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-chlorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(phenylsulfanyl)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([[(1R,3S)-3-[[(5-chloro-7-methylnaphthalen-2-yl)methyl]amino]cyclohexyl]acetyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-([[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-amino-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-Bromomyristic acid
-
-
2-bromomyristoyl-CoA
-
-
2-dodecylglycidoyl-S-CoA
IC50 below 1 mM
2-Fluoromyristic acid
-
-
2-fluoromyristoyl-CoA
-
-
2-Fluorotetradecan-1-ol
-
-
2-Hydroxymyristic acid
-
-
2-hydroxymyristoyl-CoA
-
-
2-oxo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide
-
-
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
2-[(4-methoxybenzyl)amino]-5,5-dimethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carbonitrile
-
-
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-5-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-(3-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: 0.0019 mM
2-[(cyclohexylcarbonyl)amino]-N-(4-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-5-carboxamide
IC50: 0.0068 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-7-carboxamide
IC50: 0.001 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-5-carboxamide
IC50: 0.0011 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-6-carboxamide
IC50: 0.00029 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
2-[(cyclohexylmethyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.001 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[(methanesulfonyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
2-[([(1R,3S)-3-[(1-benzofuran-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1H-indol-5-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
2-[[3-methyl-2-(2-phenylethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
2-[[3-methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
3',5'-dichloro-4'-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]biphenyl-3-carboxamide
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
3,5-dichloro-3'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-3'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-4'-[(4-methylpiperazin-1-yl)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3,5-dichloro-4'-[(diethylamino)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)biphenyl-4-sulfonamide
-
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-[(pyridin-3-yl)methyl]propan-1-amine
3-butyl-4-(but-3-yn-1-ylsulfanyl)-6-methoxy-2-methylquinoline
-
-
3-butyl-6-methoxy-2-methyl-4-[(2-phenylethyl)sulfanyl]quinoline
-
-
3-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
3-tetradecyn-1-ol
IC50 above 100 mM
3-[(2-bromo-3-butyl-6-methoxyquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propan-1-ol
-
-
3-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-butyl-6-methoxyquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(3-ethyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[(6-methoxy-2-methylquinolin-4-yl)sulfanyl]propanenitrile
-
-
3-[[3-methyl-2-[[2,3,4-tris(fluoranyl)phenoxy]methyl]-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine
i.e. Ro-09-4879
4-(1H-pyrazol-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5-dihydroxybenzamide
4-(4-chloro-2-[5-[(trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]phenoxy)piperidine
high affinity inhibitor of Leishmania donovani, does not not display significant selectivity for Leishmania donovania over the human enzyme. Compound does not display any macrophage toxicity up to 0.09 mM
4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
-
-
4-bromo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
-
4-bromo-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-bromo-N-(2-methylpropyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide
-
-
4-bromo-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-bromo-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzenesulfonamide
-
-
4-cyano-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(1H-pyrazol-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(2-methylpyridin-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-(pyridin-3-yl)benzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-phenylbenzenesulfonamide
-
-
4-methoxy-2,3,6-trimethyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzenesulfonamide
-
-
4-methyl-N-[2-[(7-methylthieno[3,2-d]pyrimidin-4-yl)sulfanyl]phenyl]benzene-1-sulfonamide
4-[(2-[5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-benzothiophen-3-yl)oxy]piperidine
4-[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]butanenitrile
-
-
4-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
4-[(4-bromophenoxy)methyl]-1,3,5-trimethyl-1H-pyrazole
-
-
4-[[(4-bromophenyl)sulfonyl]methyl]-1,3,5-trimethyl-1H-pyrazole
-
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
5-chloro-N-[4-(4-fluorophenoxy)phenyl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide
5-methyl-N-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]-1-phenyl-1H-pyrazole-4-sulfonamide
6-(2-methyl-1,3-thiazol-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-(benzylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-(morpholin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-([2-[4-(propan-2-yl)piperazin-1-yl]ethyl]amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-ethyl-3-(trifluoromethyl)-2,3-dihydro-1,4-benzoxathiine 4,4-dioxide
-
-
6-[(1H-indol-5-ylmethyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[2-(4-methylpiperazin-1-yl)ethylamino]pyridine-3-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide
-
-
6-[3-(piperazin-1-yl)piperidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[3-(piperazin-1-yl)pyrrolidin-1-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(1-methylpiperidin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(1H-imidazol-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-benzylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-methylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(4-phenylpiperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(morpholin-4-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(piperazin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[2-(piperidin-1-yl)ethyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[3-(dimethylamino)propyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
6-[[4-[(dimethylamino)methyl]benzyl](methyl)amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide
-
-
Ala-Leu-Tyr-Ala-Ser-Lys-Leu-Ser
-
competitve against peptide substrate Gly-Leu-Tyr-Ala-Ser-Lys-Leu-Ser
benzyl-{3-[2-(2-ethoxymethyl-benzofuran-5-ylmethoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-amine
-
-
Ca2+
40% inhibition at 5 mM, activation at lower concentrations below 0.25 mM
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
CoA
-
noncompetitive
CP-014553
CP-030890-27
D-Ala-Leu-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Phe-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Tyr-Ala-Ala-Ala-Ala-Arg-Arg
-
-
D-Ala-Val-Ala-Ala-Ala-Ala-Arg-Arg
-
-
DDD85646
diethyldicarbonate
-
-
enolase
-
ethyl 1-[4-[(4-methoxybenzene-1-sulfonyl)amino]phenyl]-3,5-dimethyl-1H-pyrazole-4-carboxylate
ethyl 3-(1-methylethyl)-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-cyclopropyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-ethyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-(3-piperidin-1-ylpropoxy)-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-(1-hydroxyethyl)quinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-chloroquinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-fluoroquinoline-3-carboxylate
-
-
ethyl 4-(but-3-yn-1-ylsulfanyl)-6-methylquinoline-3-carboxylate
-
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
ethyl 4-[(2-cyanoethyl)amino]quinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-ethylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-methylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-2-propylquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-methoxyquinoline-3-carboxylate
-
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
ethyl 4-[(2-cyanoethyl)sulfanyl]quinoline-3-carboxylate
-
-
ethyl 4-[2-(benzylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-(tert-butylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-hydroxy-3-(isopropylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
-
ethyl 4-[2-hydroxy-3-[(2-methylpropyl)amino]propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 4-[3-(tert-butylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[3-[(2,2-dimethylpropyl)amino]-2-hydroxypropoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[4-(tert-butylamino)butoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[[5-(tert-butylamino)pentyl]oxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
ethyl 6-acetyl-4-(but-3-yn-1-ylsulfanyl)quinoline-3-carboxylate
-
-
factor NIP71
-
heat shock cognate protein 70
-
histamine
-
noncompetitive
HIV1 Nef protein N-terminal peptide
Nef peptide acts as a competitive inhibitor for the myristoylation of Gag; Nef peptide acts as a competitive inhibitor for the myristoylation of Gag
-
Inhibitor protein from bovine brain
-
located in the membrane fraction, heat-stable, monomeric, 71 kDa
-
L-histidinol
-
noncompetitive, reversible by L-histidine
lauric acid
IC50 below 1 mM
m-calpain
-
enzyme is inactivated by cleavage, protease is specific for PEST regions, i.e. regions rich in proline, glutamic acid, serine and threonine, calpain-inhibitor calpastatin protects
-
Mn2+
50% inhibition at 5 mM
myristelaidic acid
IC50 below 1 mM
myristic acid
IC50 in the range 1-100 mM
myristoleic acid
IC50 below 1 mM
myristoyl-carba(dethia)-CoA
-
-
N(2-S-CoA-tetradecanoyl)glycinamide
IC50 below 1 mM
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
N-(1-propyl-3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-(3,4-dimethyl-1,2-oxazol-5-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1-propyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-(4-bromobenzyl)-1,3,5-trimethyl-1H-pyrazol-4-amine
-
-
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-carboxamide
-
-
N-(4-bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide
-
-
N-(6-[[N-(biphenyl-4-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclopentanecarboxamide
IC50: 0.00016 mM
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
N-(imidazo[1,2-a]pyridin-3-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
N-benzyl-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-methyl-5-[5-[(2S)-1-(1-methylpiperidin-4-yl)pyrrolidin-2-yl]-1,2,4-oxadiazol-3-yl]pyridin-2-amine
-
inhibitor identified by virtual screening. Compound shows hydrophobic interactions with Phe82, Tyr209, Val370, and Leu391 and hydrogen bonds with Asn159, Tyr318, and Val370. Binding of the compound may stabilize the enzyme
N-Myristoylglycylpeptides
-
-
-
N-myristoyltransferase inhibitor protein 71
-
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
N-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)oxy]aniline
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
N-[(pyridin-3-yl)methyl]-3-([2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzothiazol-7-yl]oxy)propan-1-amine
N-[1,3-dimethyl-5-(morpholin-4-yl)-1H-pyrazol-4-yl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide
-
-
N-[2-chloro-5-[(3S,4R)-1-[4-(4-chlorophenyl)-3-hydroxybutanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]phenyl]-2-(4-fluorophenyl)acetamide
N-[2-[(2-methylpropanoyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000033 mM
N-[2-[(cyclobutylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000023 mM
N-[2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000081 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000012 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[[(4-phenylcyclohexa-1,5-dien-1-yl)methyl]amino]cyclohexanecarboxamide
IC50: 0.00013 mM
N-[2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000024 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylmethyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]phenyl]acetamide
-
-
N-[5-[(4R)-1-[(3R)-3-amino-4-(4-chlorophenyl)butanoyl]-4-(hydroxymethyl)pyrrolidin-3-yl]-2-chlorophenyl]-2-(4-fluorophenyl)acetamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-([4-[(naphthalen-2-ylmethyl)amino]butanoyl]amino)-1,3-benzothiazol-2-yl]cyclopentanecarboxamide
IC50: 0.000015 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
Octapeptide inhibitors with hydrophobic amino acid in position 2
-
-
-
p-hydroxymercuribenzoate
-
-
palmitic acid
IC50 in the range 1-100 mM
palmitoyl-CoA
protein NIP71
-
protein from bovine brain
-
S-(2-bromotetradecanoyl)-CoA
IC50 below 1 mM
S-(2-ketopentadecyl)-CoA
IC50: 0.00006 mM
S-(2-Oxo)-pentadecyl-CoA
S-(2-oxo)pentadecyl-CoA
S-(3-Oxohexadecyl)-CoA
-
-
SC-58272
serinal bisulfite
-
-
tert-butyl 4-[2-([5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]pyridin-2-yl]amino)ethyl]piperazine-1-carboxylate
-
-
tert-butyl [6-([2-[(naphthalen-2-ylmethyl)amino]ethyl]carbamoyl)-1,3-benzothiazol-2-yl]carbamate
IC50: above 0.01 mM
tetradecyl trimethylammonium bromide
IC50 above 100 mM
tetradecyl triphenylphosphonium bromide
IC50 above 100 mM
trans-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.000034 mM
Zn2+
80% inhibition at 5 mM
[(3-butyl-6-methoxy-2-methylquinolin-4-yl)sulfanyl]acetonitrile
-
-
[4-[3-(benzylamino)propoxy]-3-methyl-1-benzofuran-2-yl](1-methyl-1H-imidazol-2-yl)methanone
{3-[2-(1H-imidazol-2-yl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2,3-difluoro-phenoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2-ethoxymethyl-benzofuran-5-yloxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
additional information
-